Boston-based Karuna Therapeutics, focused on the treatment of neuropsychiatric disorders including psychosis in schizophrenia, psychosis in Alzheimer’s disease, and pain, has announced the completion of a $68 million Series B financing round, including the issuance of $5 million in shares upon conversion of debt into equity. KarXT, Karuna’s lead product candidate, is currently being evaluated […]

High Purity New England, a supplier of biotech equipment, has signed a lease for a substantial new building, formerly occupied by Alexion, where they will nearly quadruple their manufacturing footprint and expand their offices in northern Rhode Island. High Purity New England has seen a surge of growth in the past 6 years, having grown […]

Voyager Therapeutics and AbbVie have announced an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies for the potential treatment of Parkinson’s disease and other diseases (synucleinopathies) characterized by the abnormal accumulation of misfolded alpha-synuclein protein. The delivery of sufficient quantities of antibodies across the blood-brain barrier is one of the […]

Biogen has announced plans to acquire Nightstar Therapeutics (NST), a clinical-stage gene therapy company based in London, UK. NSK is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. Under the terms of the proposed acquisition, Biogen will pay $25.50 in cash for each NSK share, representing a total transaction value of about $800 […]

Cambridge-based Voyager Therapeutics and Neurocrine Biosciences  and have announced the formation of a strategic collaboration focused on the development and commercialization of Voyager’s gene therapy programs for Parkinson’s disease and Friedreich’s ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences’ expertise in neuroscience, drug development and commercialization with […]

The separation of Ironwood Pharmaceuticals into two independent, publicly traded companies, Ironwood and Cyclerion Therapeutics, first announced in May 2018, is on track to be completed during the first half of 2019; and both companies have named women to lead their new boards of directors. Julie McHugh will serve as chair of the new Ironwood […]

The separation of Ironwood Pharmaceuticals into two independent, publicly traded companies, first announced in May 2018, is on track to be completed during the first half of 2019. In early January, Ironwood announced the appointment of the CEOs of the two companies, to become effective at the time of the separation. Industry veteran Mark Mallon […]

Kyn Therapeutics, a Boston-based, clinical-stage biotech launched in December 2017 has announced a global strategic collaboration with Celgene to develop novel immuno-oncology therapies. The collaboration unites Kyn’s immuno-oncology expertise and pipeline with Celgene’s capabilities for developing and commercializing medicines in areas of high unmet medical need. It gives Celgene exclusive options to license Kyn’s aryl […]

Cambridge-based biotech Obsidian Therapeutics has announced a strategic collaboration with Celgene for the discovery and development of novel, regulated cell therapies that utilize Obsidian’s Destabilizing Domain (DD) technology. Specifically, the collaboration is based on Obsidian’s DD technology for the controlled expression of IL12 and CD40L, two immunomodulatory factors that have the potential to augment the […]

Eli Lilly and Loxo Oncology have announced a definitive agreement for Lilly to acquire Loxo for $235 per share in cash, or approximately $8.0 billion. Headquartered in Stamford, Connecticut, Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be […]